Issue link: https://optometricmanagementsupplements.epubxp.com/i/571093
S E P T E M B E R 2 0 1 5 • O P T O M E T R I C M A N A G E M E N T . C O M S 21 such as diabetes, hypertension, and certain cancers, ofen frst exhibit in the periphery of the retina, therefore regular screening plays a vital role in preventing loss of sight and detecting the onset of systematic dis- eases. optomap images taken at routine eye examinations provide digital records that can be compared over time to monitor dis- ease progression and manage treatment. ENGINEERING AND INNOVATING ULTRA-WIDEFIELD RETINAL IMAGING Over the past fve years with the delivery of Daytona and California ultra-widefeld retinal imaging devices, the ophthalmic feld has embraced our technology allow- ing us to invest more in research and de- velopment. Tese products provide eyecare professionals with the very latest, clinical- ly-validated retinal imaging capabilities. Some of the many benefts of these devices are they are both smaller, which is impor- tant in ever shrinking exam lanes, and they ofer more imaging modalities such as autofuorescence. Fundus autofuorescence images the RPE and can detect changes and disease that would not be identifed in a color fundus image. California also ofers the ability to do fuorescein and indocyanine green angiography procedures. In the near future, a combined ultra-widefeld retinal imaging technology and integrated optical coherence to- mography (OCT) will have the potential to ofer eyecare professionals the most powerful tools for disease discov- ery and management. Te combination of UWF and the specifc data that can be derived from OCT, in a single device, will be a game-changing combination. A STANDARD OF CARE Our goal is to drive a company-wide focus on optomap becoming a standard of care for retinal examinations. Te intent is to support a patient's journey across the spec- trum of care, from optometric retinal exams to ophthal- mology to vitro-retinal specialists if necessary. We frmly believe optomap will provide doctors the tools they need for more efective detection, intervention and treatment for their patients. Supporting our goal to be a standard of care is a pub- lished clinical study showing that a non-dilated ultra- widefeld image is considered equivalent to the ETDRS Gold standard. Another study published in 2015 showed that diabetic eyes with predominantly peripheral lesions (defned as outside of ETDRS 7 standard feld) had a 4.7 fold increased risk of progression to proliferative diabetic retinopathy (PDR). Tese lesions, because they are outside of the standard feld evaluated, may have gone unnoticed without the use of our ultra-widefeld retinal imaging. Tese published results are the reason Optos is diligent about pursuing optomap as an integral part of all compre- hensive eye examinations. CONCLUSION With our continued innovation and the interest by the oph- thalmic community, underpinned by an increasing body of supportive clinical evidence as well as the upcoming launch of new products, we are confdent that Optos will remain a key player in the future of retinal imaging. We remain steadfast in our determination to help eyecare professionals care for their patients by providing the best tools possible OPTOME TRIC MANAGEMENT CORPORATE PROFILE optomap image vs. traditional retinal imaging techniques The progression of Optos ultra-widefeld retinal imaging devices S P O N S O R E D B Y O P T O S